Skip to main content
Top

26-08-2013 | Gynecologic cancers | Book chapter | Article

1. Ovarian Cancer

Authors: Hebert Alberto Vargas, MD, Pier Luigi Di Paolo, MD, Asim Afaq, MD, Oguz Akin, MD

Publisher: Springer New York

Abstract

The ovaries are paired pelvic organs typically found below the bifurcation of the common iliac vessels lateral to the uterus. They are responsible for hormone secretion and the production of female reproductive cells. Histologically, the ovaries are composed of follicles embedded in a mesh of stroma formed of connective tissue and spindle cells and covered by a layer of surface epithelium. Abnormal proliferation of any of the tissue types can result in both benign and malignant ovarian tumors.
Literature
1.
Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36. doi:10.​3322/​caac.​20121.PubMedCrossRef
2.
Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol. 1991;9:1138–50.PubMed
3.
Ramirez I. The role of surgery in the management of epithelial ovarian cancer. Cancer Control. 2011;18:22–30.PubMed
4.
Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53. doi:10.​1056/​NEJMoa0908806.PubMedCrossRef
5.
Jung SE, Lee JM, Rha SE, Byun JY, Jung JI, Hahn ST. CT and MR imaging of ovarian tumors with emphasis on differential diagnosis. Radiographics. 2002;22:1305–25.PubMedCrossRef
6.
Timmerman D, Ameye L, Fischerova D, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ. 2010;341:c6839. doi:10.​1136/​bmj.​c6839.PubMedCrossRef
7.
Spencer JA, Gore RM. The adnexal incidentaloma: a practical approach to management. Cancer Imaging. 2011;11:48–51. doi:10.​1102/​1470-7330.​2011.​0008.PubMedCrossRef
8.
Levine D, Brown DL, Andreotti RF, et al. Management of asymptomatic ovarian and other adnexal cysts imaged at US Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology. 2010;256:943–54. doi:10.​1148/​radiol.​10100213.PubMedCrossRef
9.
Spencer JA, Forstner R, Cunha TM, Kinkel K. ESUR guidelines for MR imaging of the sonographically indeterminate adnexal mass: an algorithmic approach. Eur Radiol. 2010;20:25–35.PubMedCrossRef
10.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
11.
FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2009;105:3–4.CrossRef
12.
Mironov O, Ishill NM, Mironov S, et al. Pleural effusion detected at CT prior to primary cytoreduction for stage III or IV ovarian carcinoma: effect on survival. Radiology. 2011;258:776–84.PubMedCrossRef
13.
Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ. Staging of advanced ovarian cancer: comparison of imaging modalities–report from the Radiological Diagnostic Oncology Group. Radiology. 2000;215:761–7.PubMed
14.
Coakley FV. Staging ovarian cancer: role of imaging. Radiol Clin North Am. 2002;40:609–36. doi:10.​1007/​s00330-010-1886-4.PubMedCrossRef
15.
Forstner R, Sala E, Kinkel K, Spencer JA. ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol. 2010;20:2773–80.PubMedCrossRef
16.
Ricke J, Sehouli J, Hach C, Hanninen EL, Lichtenegger W, Feliz R. Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol. 2003;13:943–9. doi:10.​1148/​radiol.​2482070371.PubMedCrossRef
17.
Akin O, Sala E, Moskowitz CS, et al. Perihepatic metastases from ovarian cancer: sensitivity and specificity of CT for the detection of metastases with and those without liver parenchymal invasion. Radiology. 2008;248:511–7. doi:10.​1148/​radiol.​10100162.PubMedCrossRef
18.
Rustin G, Tuxen M. Use of CA 125 in follow-up of ovarian cancer. Lancet. 1996;348(9021):191–2. doi:S0140673696240292 [pii].PubMedCrossRef
19.
Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995;21:215–45.PubMedCrossRef
20.
Folk JJ, Botsford M, Musa AG. Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure. Gynecol Oncol. 1995;57:178–82. doi:10.​1006/​gyno.​1995.​1121.PubMedCrossRef
21.
Patsner B, Orr Jr JW, Mann Jr WJ, Taylor PT, Partridge E, Allmen T. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease? Gynecol Oncol. 1990;38:373–6. doi:10.​1016/​0090-8258(90)90076-W [pii].PubMedCrossRef
22.
Rubin SC, Hoskins WJ, Hakes TB, et al. Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol. 1989;160:667–71.PubMedCrossRef
23.
Low RN, Duggan B, Barone RM, Saleh F, Song SY. Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year. Radiology. 2005;235:918–26.PubMedCrossRef